Virpax Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $10.37 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Virpax Pharmaceuticals Inc had its IPO on 2021-02-17 under the ticker symbol VRPX.
The company operates in the Healthcare sector and Biotechnology industry. Virpax Pharmaceuticals Inc has a staff strength of 7 employees.
Shares of Virpax Pharmaceuticals Inc opened at $0.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.77 - $0.85, and closed at $0.81.
This is a +3.33% increase from the previous day's closing price.
A total volume of 30,187 shares were traded at the close of the day’s session.
In the last one week, shares of Virpax Pharmaceuticals Inc have slipped by -9.64%.
Virpax Pharmaceuticals Inc's Key Ratios
Virpax Pharmaceuticals Inc has a market cap of $10.37 million, indicating a price to book ratio of 0.4523 and a price to sales ratio of 0.
In the last 12-months Virpax Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Virpax Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Virpax Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -44.71% with a return of equity of -77.82%.
In Q2, Virpax Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Virpax Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Virpax Pharmaceuticals Inc’s profitability.
Virpax Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0266. Its price to sales ratio in the trailing 12-months stood at 0.
Virpax Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $15.95 million
- Total Liabilities
- $3.65 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Virpax Pharmaceuticals Inc ended 2023 with $15.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.95 million while shareholder equity stood at $12.30 million.
Virpax Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $3.65 million in other current liabilities, 117.00 in common stock, $-48987928.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.80 million and cash and short-term investments were $14.80 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Virpax Pharmaceuticals Inc’s total current assets stands at $15.95 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.
In 2023, Virpax Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Virpax Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Virpax Pharmaceuticals Inc stock is currently trading at $0.81 per share. It touched a 52-week high of $1.38 and a 52-week low of $1.38. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $0.91 and 200-day moving average was $0.86 The short ratio stood at 1.46 indicating a short percent outstanding of 0%.
Around 2571% of the company’s stock are held by insiders while 1181.2% are held by institutions.
Frequently Asked Questions About Virpax Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company’s preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.